Published in Cancer Res on March 01, 2003
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell (2009) 1.77
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol (2006) 1.45
Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol (2012) 1.33
Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) (2011) 1.29
Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin. Gastroenterology (2006) 1.18
MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol (2013) 1.17
Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol (2014) 1.16
Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal (2009) 1.16
Conditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality. J Invest Dermatol (2010) 1.09
Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PLoS One (2008) 1.08
Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut (2007) 1.03
Effects of activin and TGFβ on p21 in colon cancer. PLoS One (2012) 1.01
The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol (2010) 1.00
Both microsatellite length and sequence context determine frameshift mutation rates in defective DNA mismatch repair. Hum Mol Genet (2010) 0.97
Flanking sequence specificity determines coding microsatellite heteroduplex and mutation rates with defective DNA mismatch repair (MMR). Oncogene (2010) 0.95
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability. BMC Cancer (2008) 0.95
Chromosomal imbalances in the colorectal carcinomas with microsatellite instability. Am J Pathol (2003) 0.93
Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol (2008) 0.92
Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog Mol Biol Transl Sci (2010) 0.91
Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms. PLoS One (2009) 0.89
The Notch ligand Delta-like 1 integrates inputs from TGFbeta/Activin and Wnt pathways. Exp Cell Res (2011) 0.88
Activin A balance regulates epithelial invasiveness and tumorigenesis. Lab Invest (2014) 0.87
The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy. Curr Cancer Drug Targets (2010) 0.83
Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within activin receptor 2 (ACVR2). Mutat Res (2011) 0.83
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer (2012) 0.82
De Novo proteome analysis of genetically modified tumor cells by a metabolic labeling/azide-alkyne cycloaddition approach. Mol Cell Proteomics (2014) 0.82
Genetics and pathology of pancreatic cancer. HPB (Oxford) (2006) 0.82
High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma. Oncotarget (2016) 0.80
A large MSH2 Alu insertion mutation causes HNPCC in a German kindred. Hum Genet (2004) 0.80
Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Mol Cancer (2014) 0.80
Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras. J Gastroenterol (2015) 0.78
Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma. Oncotarget (2015) 0.77
Esophageal squamous cell carcinoma invasion is inhibited by Activin A in ACVRIB-positive cells. BMC Cancer (2016) 0.76
A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer. Oncotarget (2016) 0.75
Coding Microsatellite Frameshift Mutations Accumulate in Atherosclerotic Carotid Artery Lesions: Evaluation of 26 Cases and Literature Review. Mol Med (2015) 0.75
Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects. Cancer Biol Ther (2009) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A (2008) 6.59
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
The antisense transcriptomes of human cells. Science (2008) 6.29
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet (2003) 5.51
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc (2007) 5.15
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12